Scottish nebulizer developer Nebu-Flow has raised £1.7 million “to continue the commercialization and delivery of next generation respiratory pharmaceuticals,” the company has announced on social media. The funding round was led by Foresight Williams Technology. Nebu-Flow was spun out from the University of Glasgow in 2019 to develop a device based on surface acoustic wave (SAW) aerosolization technology.
The company’s posts included links to an article on insider.co.uk in which Nebu-Flow CEO Elijah Nazarzadeh commented, “Our technology enables efficient respiratory delivery of a wider range of drugs that are hard to nebulize – many of these drugs, like biologics, are potentially life-saving – so we are pleased to have the support of Foresight and our other investors, whose ambitions for the business are very much aligned with our own.”
According to the article, newly appointed Nebu-Flow Chair John Pritchard said, “Elijah leads a highly motivated team developing pioneering technology, positioned to make a significant impact in global markets, and I look forward to continuing to guide and support the company as it enters its next phase of growth.” In addition to his keynote address at RDD 2022, Pritchard presented a talk on SAW aerosolization technology at that meeting.
Advisors to Nebu-Flow include former GSK Respiratory Centre of Excellence Head Helen Muirhead and former GSK VP Gordon Muirhead of GMPharma.
Read the insider.co.uk article.
